Advertisement
ABT vs SYK
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Both ABT and SYK have faced downward pressure in recent market activity, with shares trading near 52-week lows amid broader healthcare sector challenges.
- ABT benefits from recent FDA clearance for its Ultreon 3.0 AI-powered imaging software, bolstering cardiovascular offerings, while SYK contends with fallout from a Q1 cyberattack that led to earnings misses.
- ABT offers a higher dividend yield of 2.82% compared to SYK's 1.19%, appealing to income-focused investors.
- ABT trades at a lower forward P/E ratio (price-to-earnings) of 16.31 versus SYK's 19.65, suggesting relatively better valuation.
- Recent one-month performance shows both stocks down approximately 10-11%, but ABT exhibits lower volatility with a beta of 0.78 versus SYK's 0.93.
Introduction
Abbott Laboratories (ABT) and Stryker (SYK) are leading players in the medical technology sector, focusing on devices, diagnostics, and surgical solutions. This comparison is particularly relevant for investors and traders navigating healthcare volatility, where innovation in areas like cardiovascular imaging and orthopedics drives growth amid macroeconomic pressures and operational risks. By examining recent performance, key metrics, and market positioning, readers can assess relative strengths in this competitive space.
ABT Overview and Recent Performance
Abbott Laboratories (ABT) operates a diversified portfolio spanning diagnostics, nutritional products, pharmaceuticals, and medical devices, with strengths in cardiovascular and diabetes care. In recent weeks, ABT shares have traded near the lower end of their 52-week range (89.14-139.06), reflecting broader sector declines and reduced COVID-19 testing demand. Sentiment has been supported by positive regulatory milestones, including FDA clearance and CE Mark for the Ultreon 3.0 AI-powered coronary imaging platform, enhancing precision in stent procedures. Q1 results showed revenue of $11.16 billion and EPS (earnings per share) of $1.15, aligning with expectations despite headwinds. Lower beta (0.78) indicates relative stability, with a market cap of approximately $156 billion.
SYK Overview and Recent Performance
Stryker (SYK) specializes in orthopaedics, medical and surgical equipment, and neurotechnology, serving hospitals and ambulatory centers globally. Shares recently hit new 52-week lows (294.55-404.87) following a sharp decline, driven by a late-quarter cyberattack that disrupted Q1 operations, leading to missed revenue ($6.02 billion) and EPS ($2.60 versus estimates of $2.98). This event overshadowed organic growth and prompted analyst price target adjustments, though full-year guidance remains intact at 8-9.5% sales growth. With a market cap around $113 billion and beta of 0.93, SYK reflects heightened sensitivity to operational disruptions in recent market activity.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available models that analyze thousands of tickers across diverse strategies, timeframes from 5 minutes to daily, and asset classes. These bots deliver real-time signals for copy trading, featuring impressive stats like annualized returns ranging from +32% to +163%, win rates of 51-88%, and specialized themes such as semiconductors, data centers, and industrials. For instance, semiconductor-focused bots report up to +97% annualized returns with 63% win rates, while volatility agents exceed +90% gains. Traders can explore virtual, signal, or brokerage agents tailored to current conditions. Visit the Trending AI Robots page to evaluate performance metrics and suit your strategy.
Head-to-Head Comparison
ABT's diversified model across diagnostics and nutrition provides resilience against single-segment risks, contrasting SYK's concentrated focus on orthopaedics and surgical devices. Growth drivers for ABT include AI-enhanced diagnostics, while SYK leverages procedure volumes; both face reimbursement pressures. Recent momentum favors neither, with similar ~10% monthly declines, but ABT shows steadier trends. Risk factors highlight SYK's cyber vulnerability versus ABT's litigation exposure. Sector overlap in medtech underscores trade-offs: ABT for stability and yield, SYK for specialized growth potential post-recovery.
Tickeron AI Verdict
Tickeron's AI currently leans toward ABT based on trend stability, recent positive catalysts like Ultreon clearance, superior dividend yield, attractive forward valuation, and lower volatility. While SYK offers strong long-term positioning, near-term cyber recovery weighs on relative appeal. This probabilistic edge may shift with new data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- ABT’s TA Score: 5 bullish, 3 bearish.
- SYK’s TA Score: 5 bullish, 3 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -3.17% price change this week, while SYK (@Medical/Nursing Services) price change was +2.14% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.39%. For the same industry, the average monthly price growth was +1.95%, and the average quarterly price growth was -16.80%.
Reported Earning Dates
ABT is expected to report earnings on Jul 16, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.39% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ABT | SYK | ABT / SYK | |
| Capitalization | 154B | 120B | 128% |
| EBITDA | 11.8B | 6.44B | 183% |
| Gain YTD | -28.819 | -10.933 | 264% |
| P/E Ratio | 24.70 | 36.13 | 68% |
| Revenue | 45.1B | 25.3B | 178% |
| Total Cash | 7.3B | 2.97B | 246% |
| Total Debt | 34B | 14.7B | 231% |
ABT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 64 | |
SMR RATING 1..100 | 64 | 57 | |
PRICE GROWTH RATING 1..100 | 63 | 60 | |
P/E GROWTH RATING 1..100 | 23 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (3) in the Medical Specialties industry is in the same range as SYK (10). This means that ABT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for ABT (100). This means that SYK’s stock grew somewhat faster than ABT’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as ABT (64). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
SYK's Price Growth Rating (60) in the Medical Specialties industry is in the same range as ABT (63). This means that SYK’s stock grew similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (23) in the Medical Specialties industry is somewhat better than the same rating for SYK (81). This means that ABT’s stock grew somewhat faster than SYK’s over the last 12 months.
| ABT | SYK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 49% | 4 days ago 50% |
| Stochastic ODDS (%) | 4 days ago 54% | 4 days ago 60% |
| Momentum ODDS (%) | 4 days ago 50% | 4 days ago 60% |
| MACD ODDS (%) | 4 days ago 57% | 4 days ago 75% |
| TrendWeek ODDS (%) | 4 days ago 54% | 4 days ago 54% |
| TrendMonth ODDS (%) | 4 days ago 49% | 4 days ago 46% |
| Advances ODDS (%) | 11 days ago 53% | 11 days ago 55% |
| Declines ODDS (%) | 20 days ago 53% | 5 days ago 53% |
| BollingerBands ODDS (%) | 4 days ago 53% | 4 days ago 67% |
| Aroon ODDS (%) | 4 days ago 48% | 4 days ago 47% |
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with SYK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then SYK could also see price increases.